Literature DB >> 24858851

Ca2+/calmodulin-dependent protein kinase II increases the susceptibility to the arrhythmogenic action potential alternans in spontaneously hypertensive rats.

Hirofumi Mitsuyama1, Hisashi Yokoshiki2, Masaya Watanabe1, Kazuya Mizukami1, Junichi Shimokawa1, Hiroyuki Tsutsui1.   

Abstract

Action potential duration alternans (APD-ALT), defined as long-short-long repetitive pattern of APD, potentially leads to lethal ventricular arrhythmia. However, the mechanisms of APD-ALT in the arrhythmogenesis of cardiac hypertrophy remain undetermined. Ca(2+)/calmodulin-dependent protein kinase II (CaMKII) is known to modulate the function of cardiac sarcoplasmic reticulum and play an important role in Ca(2+) cycling. We thus aimed to determine the role of CaMKII in the increased susceptibility to APD-ALT and arrhythmogenesis in the hypertrophied heart. APD was measured by high-resolution optical mapping in left ventricular (LV) anterior wall from normotensive Wistar-Kyoto (WKY; n = 10) and spontaneously hypertensive rats (SHR; n = 10) during rapid ventricular pacing. APD-ALT was evoked at significantly lower pacing rate in SHR compared with WKY (382 ± 43 vs. 465 ± 45 beats/min, P < 0.01). These changes in APD-ALT in SHR were completely reversed by KN-93 (1 μmol/l; n = 5), an inhibitor of CaMKII, but not its inactive analog, KN-92 (1 μmol/l; n = 5). The magnitude of APD-ALT was also significantly greater in SHR than WKY and was completely normalized by KN-93. Ventricular fibrillation (VF) was induced by rapid pacing more frequently in SHR than in WKY (60 vs. 10%; P < 0.05), which was also abolished by KN-93 (0%, P < 0.05). Western blot analyses indicated that the CaMKII autophosphorylation at Thr287 was significantly increased in SHR compared with WKY. The increased susceptibility to APD-ALT and VF during rapid pacing in hypertrophied heart was prevented by KN-93. CaMKII could be an important mechanism of arrhythmogenesis in cardiac hypertrophy.
Copyright © 2014 the American Physiological Society.

Entities:  

Keywords:  APD alternans; CaMKII; cardiac hypertrophy

Mesh:

Substances:

Year:  2014        PMID: 24858851     DOI: 10.1152/ajpheart.00387.2012

Source DB:  PubMed          Journal:  Am J Physiol Heart Circ Physiol        ISSN: 0363-6135            Impact factor:   4.733


  6 in total

1.  Blockade of CaMKII depresses conduction preferentially in the right ventricular outflow tract and promotes ischemic ventricular fibrillation in the rabbit heart.

Authors:  Mark Warren; Katie J Sciuto; Tyson G Taylor; Vivek Garg; Natalia S Torres; Junko Shibayama; Kenneth W Spitzer; Alexey V Zaitsev
Journal:  Am J Physiol Heart Circ Physiol       Date:  2017-01-27       Impact factor: 4.733

2.  Calm down when the heart is stressed: Inhibiting calmodulin-dependent protein kinase II for antiarrhythmias.

Authors:  Dayue Darrel Duan
Journal:  Trends Cardiovasc Med       Date:  2015-02-07       Impact factor: 6.677

3.  CaMKII-dependent late Na+ current increases electrical dispersion and arrhythmia in ischemia-reperfusion.

Authors:  Taylor Howard; Amara Greer-Short; Tony Satroplus; Nehal Patel; Drew Nassal; Peter J Mohler; Thomas J Hund
Journal:  Am J Physiol Heart Circ Physiol       Date:  2018-06-22       Impact factor: 4.733

4.  Effects of Wenxin Keli on Cardiac Hypertrophy and Arrhythmia via Regulation of the Calcium/Calmodulin Dependent Kinase II Signaling Pathway.

Authors:  Xinyu Yang; Yu Chen; Yanda Li; Xiaomeng Ren; Yanwei Xing; Hongcai Shang
Journal:  Biomed Res Int       Date:  2017-05-09       Impact factor: 3.411

5.  CaMKII inhibition reduces isoproterenol-induced ischemia and arrhythmias in hypertrophic mice.

Authors:  Ying Feng; Jun Cheng; Baozhu Wei; Yanggan Wang
Journal:  Oncotarget       Date:  2017-03-14

6.  Sodium nitrite exerts an antihypertensive effect and improves endothelial function through activation of eNOS in the SHR.

Authors:  Wei Chih Ling; Dharmani Devi Murugan; Yeh Siang Lau; Paul M Vanhoutte; Mohd Rais Mustafa
Journal:  Sci Rep       Date:  2016-09-12       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.